Search

Your search keyword '"Lisi V"' showing total 269 results
Start Over Author "Lisi V"
269 results on '"Lisi V"'

1. Validation of an Integrated Management of Childhood Illness algorithm for managing common skin conditions in Fiji

Author

Andrew C Steer, Lisi V Tikoduadua, Emmalita M Manalac, Samantha Colquhoun, Jonathan R Carapetis, and Carolyn Maclennan

Subjects
Public aspects of medicine, RA1-1270
Abstract

OBJECTIVE: To assess the sensitivity of an Integrated Management of Childhood Illness (IMCI) algorithm to detect common skin conditions in children in Fiji. METHODS: We collected data from the assessments of children aged between 2 months and 5 years who presented to one of two health clinics. Every child was assessed by a nurse trained in the use of the IMCI algorithm and also an expert paediatrician. We used a kappa statistic to measure agreement between the nurse/algorithm assessment method and the paediatrician's diagnosis. FINDINGS: High sensitivity for identifying skin problems (sensitivity: 98.7%; 95% confidence interval, CI: 95.5-99.9) was found for the algorithm applied by IMCI-trained nurses, who were able to identify the one child with a severe skin infection and all three children with periorbital cellulitis. Sensitivity was high for the classification of abscess/cellulitis (sensitivity: 95%; 95% CI: 75.1-99.9) and infected scabies (sensitivity: 89.1%; 95% CI: 77.8-95.9), but lower for identification of impetigo, fungal infection and, in particular, non-infected scabies. CONCLUSION: The IMCI skin algorithm is a robust tool that should be incorporated into the IMCI after some modifications relating to scabies and impetigo. Its use by primary health-care workers will reduce the burden of skin diseases in children in Fiji through improved case identification and management. The algorithm should be considered in other countries where skin diseases in children are a priority, particularly in the Pacific region.

Published
2009

2. Robust Axonal Regeneration Occurs in the Injured CAST/Ei Mouse CNS

Author

Omura, T, Omura, K, Tedeschi, A, Riva, P, Painter, MW, Rojas, L, Martin, J, Lisi, V, Huebner, EA, Latremoliere, A, Yin, Y, Barrett, LB, Singh, B, Lee, S, Crisman, T, Gao, F, Li, S, Kapur, K, Geschwind, DH, Kosik, KS, Coppola, G, He, Z, Carmichael, ST, Benowitz, LI, Costigan, M, and Woolf, CJ

Subjects
Neurology & Neurosurgery, Neurosciences, Cognitive Sciences, Psychology
Abstract

Axon regeneration in the CNS requires reactivating injured neurons' intrinsic growth state and enabling growth in an inhibitory environment. Using an inbred mouse neuronal phenotypic screen, we find that CAST/Ei mouse adult dorsal root ganglion neurons extend axons more on CNS myelin than the other eight strains tested, especially when pre-injured. Injury-primed CAST/Ei neurons also regenerate markedly in the spinal cord and optic nerve more than those from C57BL/6 mice and show greater sprouting following ischemic stroke. Heritability estimates indicate that extended growth in CAST/Ei neurons on myelin is genetically determined, and two whole-genome expression screens yield the Activin transcript Inhba as most correlated with this ability. Inhibition of Activin signaling in CAST/Ei mice diminishes their CNS regenerative capacity, whereas its activation in C57BL/6 animals boosts regeneration. This screen demonstrates that mammalian CNS regeneration can occur and reveals a molecular pathway that contributes to this ability. Omura et al. screened for neuronal growth on myelin and find CAST/Ei inbred mice are uniquely able to regenerate axons in the injured CNS through Activin signaling. Enhancing Activin signaling confers a CNS-regenerative capacity in normally non-regenerative mouse strains.

Published
2015

5. SARS-CoV-2 antibody dynamics, within-household transmission and the impact of contact tracing from community-wide serological testing in the Italian Municipality of Vo’

Author

Dorigatti, I, Lavezzo, E, Manuto, L, Ciavarella, C, Pacenti, M, Boldrin, C, Cattai, M, Saluzzo, F, Franchin, E, Del Vecchio, C, Caldart, F, Castelli, G, Nicoletti, M, Nieddu, E, Salvadoretti, E, Labella, B, Fava, L, Guglielmo, S, Fascina, M, Alvisi, G, Vanuzzo, MC, Zupo, T, Calandrin, R, Lisi, V, Rossi, L, Castigliuolo, I, Merigliano, S, Unwin, HJT, Plebani, M, Padoan, A, Brazzale, AR, Toppo, S, Ferguson, NM, Donnelly, C, Crisanti, A, Medical Research Council (MRC), and Wellcome Trust

Abstract

Background: In February and Mach 2020, two mass swab testing campaigns conducted in Vo’, Italy demonstrated the extent of asymptomatic SARS-CoV-2 infection and the feasibility of epidemic suppression. Methods: We tested 86% of the Vo’ population (2,602 subjects) in May with three immuno-assays detecting antibodies against the spike (S) and nucleocapsid (N) antigens, a neutralisation assay and Polymerase Chain Reaction (PCR). Subjects testing positive to PCR in February/March or a serological assay in May were tested again in November. Findings: Combining the results obtained with the three assays, we estimate a seroprevalence of 3.5% (95% Credible Interval (CrI) 2.8%-4.3%) in May. In November, all assays showed a reduction in antibody titres, though 98.8% (95% Confidence Interval (CI) 93.7%-100.0%) of sera still reacted against at least one antigen. Conversely, 18.6% (95% CI 11.0%-28.5%) showed a marked increase of antibody or viral neutralisation reactivity between May and November, linked to documented or likely re-exposures. We found significant differences in the magnitude and persistence of the antibody response by age group but not by symptom occurrence, hospitalisation, or sex. Analysis of the serostatus of 1,118 households indicated a 27.3% (95% CrI 19.2%-34.6%) probability of SARS-CoV-2 transmission among household members and that 81.8% (95% CrI 55.9%-95.2%) of transmission could be attributed to 20% of infections. Contact tracing correctly identified 44% of the infected subjects and had limited impact on the epidemic. Interpretation: We find evidence of antibody persistence up to nine months post infection. Different assays provided significantly different seroprevalence estimates, making it challenging to compare seroprevalence estimates globally. Due to the high population susceptibility and the limited impact of contact tracing, rigorous testing and improvements in contact tracing are essential to control SARS-CoV-2. Funding: Veneto Region, Medical Research Council, Wellcome Trust, Royal Society, University of Padua, UK National Institute for Health Research. Declaration of Interests: The authors declare no competing interests. Ethics Approval Statement: The first and second serosurveys of the Vo' population were approved by the Ethics Committee for Clinical Research of the province of Padova.

Published
2021

6. Author Correction: SARS-CoV-2 antibody dynamics and transmission from community-wide serological testing in the Italian municipality of Vo’ (Nature Communications, (2021), 12, 1, (4383), 10.1038/s41467-021-24622-7)

Author

Dorigatti, I., Lavezzo, E., Manuto, L., Ciavarella, C., Pacenti, M., Boldrin, C., Cattai, M., Saluzzo, F., Franchin, E., Del Vecchio, C., Caldart, F., Castelli, G., Nicoletti, M., Nieddu, E., Salvadoretti, E., Labella, B., Fava, L., Guglielmo, S., Fascina, M., Grazioli, M., Alvisi, G., Vanuzzo, M. C., Zupo, T., Calandrin, R., Lisi, V., Rossi, L., Castagliuolo, I., Merigliano, S., Unwin, H. J. T., Plebani, M., Padoan, A., Brazzale, A. R., Toppo, S., Ferguson, N. M., Donnelly, C. A., and Crisanti, A.

Published
2021

7. Validation of an Integrated Management of Childhood Illness algorithm for managing common skin conditions in Fiji/Validation d'un algorithme de gestion integree des maladies infantiles pour la prise en charge des maladies de peau courantes aux iles Fidji/Validacion de un algoritmo de la Atencion Integrada a las Enfermedades Prevalentes de la Infancia para manejar enfermedades cutaneas comunes en Fiji

Author

Steer, Andrew C., Tikoduadua, Lisi V., Manalac, Emmalita M., Colquhoun, Samantha, Carapetis, Jonathan R., and Maclennan, Carolyn

Subjects
Company business planning, Company distribution practices, Health care reform -- Planning, Skin diseases -- Distribution, Skin diseases -- Control, Skin diseases -- Diagnosis, Children -- Diseases, Children -- Distribution, Children -- Control, Children -- Diagnosis
Abstract

Objective To assess the sensitivity of an Integrated Management of Childhood Illness (IMCI) algorithm to detect common skin conditions in children in Fiji. Methods We collected data from the assessments of children aged between 2 months and 5 years who presented to one of two health clinics. Every child was assessed by a nurse trained in the use of the IMCI algorithm and also an expert paediatrician. We used a kappa statistic to measure agreement between the nurse/algorithm assessment method and the paediatrician's diagnosis. Findings High sensitivity for identifying skin problems (sensitivity: 98.7%; 95% confidence interval, CI: 95.5-99.9) was found for the algorithm applied by IMCI-trained nurses, who were able to identify the one child with a severe skin infection and all three children with periorbital cellulitis. Sensitivity was high for the classification of abscess/cellulitis (sensitivity: 95%; 95% CI: 75.1-99.9) and infected scabies (sensitivity: 89.1%; 95% Ch 77.8-95.9), but lower for identification of impetigo, fungal infection and, in particular, non-infected scabies. Conclusion The IMCI skin algorithm is a robust tool that should be incorporated into the IMCI after some modifications relating to scabies and impetigo. Its use by primary health-care workers will reduce the burden of skin diseases in children in Fiji through improved case identification and management. The algorithm should be considered in other countries where skin diseases in children are a priority, particularly in the Pacific region. Objectif Evaluer la sensibilite d'un algorithme de gestion integree des maladies infantiles (PCIME) pour la detection des maladies de peau courantes chez les enfants des iles Fidji. Methodes Nous avons recueilli des donnees sur l'evaluation d'enfants de 2 mois a 5 ans, presentes dans un des deux dispensaires participant a l'etude. Chaque enfant a ete evalue par une infirmiere formee a l'utilisation de I'algorithme de PCIME et par un pediatre expert. Nous avons utilise un test statistique Kappa pour mesurer l'accord entre l'evaluation par l'infirmiere s'aidant de l'algorithme et le diagnostic du pediatre. Resultats Nous avons releve une forte sensibilite de l'algorithme pour l'identification des problemes de peau (sensibilite: 98,7 %; intervalle de confiance a 95 %, IC: 95,5-99,9) dans le cadre de son application par les infirmieres formees a la PCIME, qui ont ete capables d'identifier parmi les enfants un cas d'affection cutanee severe et les trois cas de cellulite periorbitale. La sensibilite etait egalement bonne pour la classification des abces et des cellulites (sensibilite: 95 %, IC a 95 %: 75,1-99,9) et celle des gales infectees (sensibilite: 89,1%, IC a 95 %: 77,8-95,9), mais etait en revanche plus faible pour l'identification des impetigos et des infections fongiques, notamment des gales non infectees. Conclusion L'algorithme de PCIME pour les maladies de la peau est un outil solide, qui devrait etre integre a la PCIME apres certaines modifications concernant la gale et l'impetigo. Son utilisation par les agents de sante primaire devrait reduire la charge d'affections cutanees chez les enfants des iles Fidji en ameliorant l'identification des cas et la prise en charge. Il conviendrait d'envisager l'emploi de cet algorithme dans d'autres pays ou les affections cutanees infantiles sont une priorite, notamment dans la region Pacifique. Objetivo Determinar la sensibilidad de un algoritmo de la Atencien Integrada a las Enfermedades Prevalentes de la Infancia (AIEPI) para manejar enfermedades cutaneas comunes en les ninos en Fiji. Metodos Reunimos datos de las exploraciones a que se sometio a ninos de entre 2 meses y 5 anos atendidos en alguno de les dos dispensarios considerados. Todos les ninos fueron examinados por una enfermera adiestrada en la aplicacien del algoritmo AIEPI, asi como por un especialista en pediatria. Empleamos el estadistico kappa para medir el grade de concordancia entre el metodo de evaluacien algoritmica empleado por la enfermera y el diagnostico realizado por el pediatra. Resultados Se observe una alta sensibilidad para la deteccion de problemas cutaneos (sensibilidad: 98,7%; intervalo de confianza del 95%: 95,5-99,9) con el algoritmo aplicado por las enfermeras adiestradas en la AIEPI, que fueron capaces de identificar al unico nino que tenia una infeccion cutanea grave y a los tres ninos que padecian celulitis periorbitaria. La sensibilidad tambien fue alta en Io referente a la clasificacien de les abscesos/celulitis (sensibilidad: 95%; IC95%: 75,1-99,9) y la escabiosis infectada (sensibilidad: 89,1%; IC95%: 77,8-95,9), pero fue mas baja en la deteccion del impetigo, las micosis y, en particular, la escabiosis no infectada. Conclusion El algoritmo de diagnostico cutaneo AIEPI es un valioso instrumente que deberia integrarse en la AIEPI previa introduccien de algunos cambios relacionados con la escabiosis y el impetigo. Su aplicacien por el personal de atencien primaria permitira reducir la carga de enfermedades cutaneas en la poblacion infantil de Fiji mediante una mejor identificacion y gestion de les casos. EI uso de ese algoritmo es una posibilidad que merece considerarse tambien en otros paises donde las enfermedades cutaneas constituyen una prioridad, sobre todo en la regien riel Pacifico., Une traduction en francais de ce resume figure a la fin de l'article. Al final del articulo se facita una traduccionn al espanal. Introduction The Integrated Management of Childhood Illness [...]

Published
2009

9. Cancer prevalence estimates in Europe at the beginning of 2000

Author

Gatta, G., Mallone, S., van der Zwan, J. M., Trama, A., Siesling, S., Capocaccia, R., Hackl, M, Van Eycken, E, Henau, K, Hedelin, G, Velten, M, Launoy, G, Guizard, AV, Bouvier, AM, Maynadié, M, Woronoff, A-S, Buemi, A, Colonna, M, Ganry, O, Grosclaude, P, Holleczek, B, Ziegler, H, Tryggvadottir, L, Bellù, F, Ferretti, S, Serraino, D, Dal Maso, L, Bidoli, E, Birri, S, Zucchetto, A, Zainer, L, Vercelli, M, Orengo, MA, Casella, C, Quaglia, A, Federico, M, Rashid, I, Cirilli, C, Fusco, M, Traina, A, Michiara, M, De Lisi, V, Bozzani, F, Giacomin, A, Tumino, R, La Rosa, MG, Spata, E, Signora, A, Mangone, L, Falcini, F, Giorgetti, S, Ravaioli, A, Senatore, G, Iannelli, A, Budroni, M, Piffer, S, Franchini, S, Crocetti, E, Caldarella, A, Intrieri, T, La Rosa, F, Stracci, F, Cassetti, T, Contiero, P, Tagliabue, G, Zambon, P, Guzzinati, S, Berrino, F, Baili, P, Bella, F, Ciampichini, R, Gatta, G, Margutti, C, Micheli, A, Minicozzi, P, Sant, M, Trama, A, Caldora, M, Capocaccia, R, Carrani, E, De Angelis, R, Francisci, S, Grande, E, Inghelmann, R, Lenz, H, Martina, L, Roazzi, P, Santaquilani, M, Simonetti, A, Tavilla, A, Verdecchia, A, Langmark, F, Rachtan, J, Mężyk, R, Góżdź, S., Siudowska, U, Zwierko, M, Bielska-Lasota, M, Safaei Diba, Ch., Primic-Zakelj, M, Mateos, A, Izarzugaza, I, Torrella Ramos, A, Zurriaga, O, Marcos-Gragera, R, Vilardell, ML, Izquierdo, A, Ardanaz, E, Moreno-Iribas, C, Galceran, J, Klint, Å, Talbäck, M, Jundt, G, Usel, M, Frick, H, Ess, SM, Bordoni, A, Konzelmann, I, Dehler, S, Siesling, S, Visser, O, Otter, R, Coebergh, JWW, Greenberg, DC, Wilkinson, J, Roche, M, Verne, J, Meechan, D, Poole, J, Lawrence, G, Gavin, A, Brewster, DH, Black, RJ, and Steward, JA

Published
2013
Full Text
View/download PDF

15. 5-Fluorouracil Versus a Combination of BCNU, Adriamycin, 5- FU and Mitomycin C in Advanced Gastric Cancer: A Prospective Randomized Study of the Italian Clinical Research Oncology Group

Author

De Lisi, V., Cocconi, G., Tonato, M., Di Costanzo, F., Leonardi, F., Soldani, M., Herfarth, Ch., editor, Senn, H. J., editor, Baum, M., editor, Diehl, V., editor, von Essen, C., editor, Grundmann, E., editor, Hitzig, W., editor, Rajewsky, M. F., editor, Schlag, Peter, editor, Hohenberger, Peter, editor, and Metzger, Urs, editor

Published
1988
Full Text
View/download PDF

16. The advantage of women in cancer survival: An analysis of EUROCARE-4 data

Author

Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health

Subjects
Oncology, Male, Pathology, Cancer Research, cancer survival - women, MESH : Age Distribution, MESH : Aged, MESH: Risk Assessment, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Residence Characteristics, Neoplasms, 80 and over, Gender differences, Sex hormones, MESH: Neoplasms, MESH : Female, MESH: Residence Characteristics, Young adult, Age of Onset, MESH : Risk Assessment, MESH : Sex Distribution, MESH: Diagnosis-Related Groups, MESH: Aged, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, Relative survival, Thyroid, MESH: Sex Distribution, Middle Aged, MESH : Adult, 3. Good health, MESH : Age of Onset, Europe, MESH : Diagnosis-Related Groups, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, Female, EUROCARE, Adult, medicine.medical_specialty, Adolescent, MESH: Age of Onset, MESH : Male, MESH : Sex Factors, Population, MESH : Europe, MESH : Young Adult, Rectum, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, 03 medical and health sciences, Young Adult, Age Distribution, Sex Factors, MESH: Sex Factors, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Sex Distribution, education, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, Diagnosis-Related Groups, 030304 developmental biology, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, Cancer survival, Survival Analysis, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, Age of onset, MESH : Survival Analysis, business, MESH: Female
Abstract

We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.

Published
2009
Full Text
View/download PDF

17. Childhood cancer survival in Europe

Author

Gatta, G., Corazziari, I., Magnani, C., Peris Bonet, R., Roazzi, P., Stiller, C., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, I., Faivre, I., Chaplain, G., Carli, P. M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estève, I., Kaatsch, P., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Micheli, A., Sant, M., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Ferretti, S., Crosignani, P., Tagliabue, G., Conti, E., Vercelli, M., Pannelli, F., Mosciatti, P., Federico, Massimo, Artioli, M. E., De Lisi, V., Serventi, L., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmark, F., Andersen, A, Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Barlow, L., Möller, T., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Coleman, M. P., Black, R., and Brewster, D.

Subjects
Male, Pediatrics, medicine.medical_specialty, Adolescent, Population, Disease, Malignancy, Childhood Cancer Survival Trends, Neoplasms, medicine, Humans, Child, education, education.field_of_study, business.industry, Incidence (epidemiology), Gold standard, Age Factors, Cancer, Hematology, medicine.disease, Survival Analysis, Childhood tumours, Europe, Population-based study, Survival variation, Lymphoma, Europe, Survival Rate, Oncology, Child, Preschool, Female, Major Diagnostic Category, business
Abstract

BACKGROUND: EUROCARE-3 collected data from 45 population-based cancer registries in 20 countries on 24 620 European children aged from 0 to 14 years diagnosed with malignancy in the period 1990-1994. METHODS: Five-year survival between countries was compared for all malignancies and for the major diagnostic categories, adjusting for age, and estimated average European survival weighting for differences in childhood populations. RESULTS: For all cancers combined, survival variation was large (45% in Estonia to 90% in Iceland), and was generally low (60-70%) in eastern Europe and high (> or =75%) in Switzerland, Germany and the Nordic countries (except Denmark). The Nordic countries had the highest survival for four of the seven major tumour types: nephroblastoma (92%), acute lymphoid leukaemia (85%), CNS tumours (73%) and acute non-lymphocytic leukaemia (62%). The eastern countries had lowest survival: 89% for Hodgkin's disease, 71% for nephroblastoma, 68% for acute lymphoid leukaemia, 61% for non-Hodgkin's lymphoma, 57% for central nervous system (CNS) tumours and 29% for acute non-lymphocytic leukaemia. CONCLUSIONS: The Nordic countries represent a survival gold standard to which other countries can aspire. Since most childhood cancers respond well to treatment, survival differences are attributable to differences in access (including referral and timely diagnosis) and use of modern treatments; however, the obstacles to access and application of standard treatments probably vary markedly with country.

Published
2003
Full Text
View/download PDF

18. EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary

Author

Sant, M., Aareleid, T., Berrino, F., Bielska Lasota, M., Carli, P. M., Faivre, J., Grosclaude, P., Hédelin, G., Matsuda, T., Møller, H., Möller, T., Verdecchia, A., Capocaccia, R., Gatta, G., Micheli, A., Santaquilani, M., Roazzi, P., Lisi, D., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Hakulinen, T., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, J., Chaplain, G., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Estève, J., Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Allemani, C., Baili, P., Ciccolallo, L., Taussig, E., Carrani, E., De Angelis, R., Hartley, S., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, Aw, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmak, F., Andersen, A., Rachtan, J., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Jundt, G., Lutz, J. M., Usel, M., Coebergr, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., and Steward, J. A.

Subjects
Male, Urologic Neoplasms, medicine.medical_specialty, Lung Neoplasms, Skin Neoplasms, Genital Neoplasms, Female, Breast Neoplasms, Digestive System Neoplasms, Sex Factors, Case mix index, Testicular Neoplasms, Neoplasms, Internal medicine, Epidemiology, medicine, Humans, Registries, Thyroid Neoplasms, cancer survival, Survival rate, Testicular cancer, Survival analysis, Brain Neoplasms, business.industry, Prostatic Neoplasms, Cancer, Hematology, medicine.disease, Survival Analysis, Age-standardised relative survival, Cancer survival, Europe, International comparison, Population-based cancer registries, Lymphoma, Surgery, Europe, Survival Rate, Oncology, Head and Neck Neoplasms, Hematologic Neoplasms, Female, business
Abstract

EUROCARE-3 analysed the survival of 1815584 adult cancer patients diagnosed from 1990 to 1994 in 22 European countries. The results are reported in tables, one per cancer site, coded according to the International Classification of Diseases (ICD)-9 classification. The main findings of the tables are summarised and commented on in this article. For most solid cancers, wide differences in survival between different European populations were found, as also reported by EUROCARE-1 and EUROCARE-2, despite a remarkable (10%) overall increase in cancer survival from 1985 to 1994. Survival was highest in northern Europe (Sweden, Norway, Finland and Iceland), and fairly good in central-southern Europe (France, Switzerland, Austria and Spain). Survival was particularly low in eastern Europe, low in Denmark and the UK, and fairly low in Portugal and Malta. The mix of tumour stage at diagnosis explains much of the survival differences for cancers of the digestive tract, female reproductive system, breast, thyroid, and also skin melanoma. For tumours of the urinary tract and prostate, the differences were explained mainly by differences in diagnostic criteria and procedures. The case mix by anatomic subsite largely explains differences in survival for head and neck cancers. For oesophagus, pancreas, liver and brain cancer, with poor prognoses, survival differences were limited. Tumours, for which highly effective treatments are available, such as testicular cancer, Hodgkin's lymphoma and some haematological malignancies, had fairly uniform survival across Europe. Survival for all tumours combined (an indicator of the overall cancer care performance of a nation's health system) was better in young than old patients, and better in women than men. The affluence of countries influenced overall cancer survival through the availability of adequate diagnostic and treatment procedures, and screening programmes.

Published
2003
Full Text
View/download PDF

19. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century

Author

Coleman, M. P., Gatta, G., Verdecchia, A., Estève, J., Sant, M., Storm, H., Allemani, C., Ciccolallo, L., Santaquilani, M., Berrino, F., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Faivre, J., Chaplain, G., Carl, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estèv, Z, Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Baili, P., Micheli, A., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Roazzi, P., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P. Guzzinati S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Möller, T., Jundt, G. Lutz J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., Steward, J. A., Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], Pathology, medicine.medical_specialty, population-based cancer registries, Lung Neoplasms, Skin Neoplasms, Population, Uterine Cervical Neoplasms, Breast Neoplasms, Disease, Sex Factors, Testicular Neoplasms, Stomach Neoplasms, Neoplasms, Epidemiology, Health care, Humans, Medicine, Registries, cancer survival, Child, education, Survival rate, Survival analysis, education.field_of_study, business.industry, Age Factors, international comparison, Prostatic Neoplasms, Cancer, Hematology, medicine.disease, Survival Analysis, Cancer survival, Europe, Survival Rate, Oncology, Colonic Neoplasms, Female, Observational study, business, Demography
Abstract

Summary International differences and trends in cancer survival withinEurope are larger than can reasonably be accounted for by arte-fact, bias or chance. The geographical patterns and trends in sur-vival are often broadly consistent with geographical differences ortrends in the type of cancer, diagnostic investigations or overallinvestment in health care, and for several major cancers, support-ing evidence is available from population-based studies of clinicalinformation. Incomplete ascertainment of cancer cases, particu-larly of long-term survivors, may contribute to some regional andinternational differences in survival, however, and more system-atic information on completeness is required. We may concludethat large international differences in survival do exist for manycancers, but we should be cautious in drawing quantitative orcausal conclusions from observational survival data.We do not yet have a fully satisfactory interpretation of thesedifferences, but we have few alternatives to this type of study if weare to understand the determinants of improved outcome for allcancer patients, and to enable better planning of their health care.The EUROCARE Working Group has developed several strategiesto disentangle the various possible explanations [73]. These includefurther development of high-resolution studies to examine theimpact on survival differences of disease stage, staging techniquesand treatment; and further development of mathematical modelsof cure. Extension of systematic international survival compari-sons to other regions of the world, such as Australia, Canada, Japanand the USA, is also in progress (the CONCORD study) [22].Oncologists and epidemiologists may provide insight into thegeographic differences and trends in survival reported by thisstudy, and may suggest further lines of enquiry. Do we need morerefined studies of survival to monitor progress against cancer andto plan future cancer care? Will such analyses help us quantify theeffect of new treatments arising from recent progress in the basicsciences and genomics on population cancer survival rates? Sub-stantial human and financial resources are required to improve theoutcome of cancer treatment. Will future investments in cancerservices include matching investment to monitor their impact onsurvival and mortality?Earlier diagnosis and prompt, universal access to optimal treat-ment would be expected to reduce international differences incancer survival in Europe. To achieve this, oncologists and healthcare planners will need better information on the comparativeperformance of their health systems. Population-based cancer reg-istries provide some of the information for such comparisons, buttheir traditional output may no longer be sufficient to evaluate theeffectiveness of health systems, and especially to explain geo-graphical differences in survival. In some countries, their role isalso under threat. Confidentiality constraints recently inhibitedthe collection of cancer registration data in the UK [90], and thelinkage of cancer registrations and deaths is currently illegal inEstonia [91]. Both activities are essential for internationally com-parable survival rates. Legal protection for cancer registrationacross Europe will be required.The mission of cancer registries should be reconsidered, and thepriority shifted from classical descriptive epidemiology and geo-graphical pathology toward more analytical monitoring ofprogress against cancer, including the probability of survival andcure, the burden of cancer prevalence, and the late effects oftherapy. Several European studies of this type have been reportedrecently [3, 36, 9294] and others are in progress. Many cancer–registries are developing closer relationships with cancer clini-cians and general practitioners, and some now systematicallycollect detailed clinical information that was collected eitherirregularly or not at all in the past. These developments willimprove the power of population-based cancer data to explain dif-ferences in cancer survival, and should enhance their relevance toclinical practice.European average survival rates are useful for comparativepurposes, but they should not become the goal for cancer controlprogrammes: the benchmark should always be the highest achiev-able survival rates.The aim of exploring geographic differences in cancer survivalis not to establish international league tables or to excite nationalrivalries, but to estimate the range of survival rates, and to identifyregions or countries in which survival could be improved.

Published
2003
Full Text
View/download PDF

20. Incidence of AIDS-Defining Cancers After AIDS Diagnosis Among People with AIDS in Italy, 1986–1998

Author

Franceschi, S., Dal Maso, L., Pezzotti, P., Polesel, J., Braga, C., Pierluca Piselli, Serraino, D., Tagliabue, G., Federico, Massimo, Ferretti, S., Lisi, V., La Rosa, F., Conti, E., Budroni, M., Vicario, G., Piffer, S., Pannelli, F., Giacomin, A., Bellù, F., Tumino, R., Fusco, M., Rezza, G., For The, Cancer, and Aids Registry Linkage, Study

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Uterine Cervical Neoplasms, invasive cervical cancer, Acquired immunodeficiency syndrome (AIDS), Risk Factors, Neoplasms, Immunopathology, Internal medicine, Epidemiology, medicine, Humans, Pharmacology (medical), Registries, Sida, Sarcoma, Kaposi, Aged, Cervical cancer, Acquired Immunodeficiency Syndrome, AIDS-Related Opportunistic Infections, biology, business.industry, non-Hodgkin lymphoma, Incidence, Lymphoma, Non-Hodgkin, Incidence (epidemiology), Kaposi sarcoma, Cancer, Middle Aged, medicine.disease, biology.organism_classification, AIDS, Infectious Diseases, Italy, linkage, incidence, Immunology, Female, business, Record linkage
Abstract

A record linkage was carried out between the Italian National Registry of AIDS and 19 cancer registries. The aim was to evaluate the 1986 through 1998 trends in incidence rate (IR) of AIDS-defining cancers (ADCs) among persons with AIDS (PWA) in Italy overall and according to various characteristics. A steady decrease in IRs was found for Kaposi sarcoma (KS) in men between 1986–1992 (2.5 per 100 person-years [py]) and 1997–1998 (1.0 per 100 py). Conversely, the first decrease in IRs of KS in women (from 0.9 to 0.6 per 100 py) and of non-Hodgkin lymphoma in both genders (from 1.7 to 0.7 per 100 py) was seen between 1993–1996 and 1997–1998, thus pointing to a favorable impact of highly active antiretroviral therapies. The decline was consistent across different age and HIV transmission groups, but it was more marked in PWA with a CD4 count >50 cells/μL than in PWA with more severe immune suppression. As a proportion of AIDS cases, invasive cervical cancer increased from 1.5% in 1993–1996 to 2.4% in 1997–1998, but IRs after AIDS could not be evaluated. On account of the marked decline of KS in men in 1997–1998, the overall burden of ADCs in Italy became similar in both genders.

Published
2003
Full Text
View/download PDF

21. PALLIATIVE CARE FOR TERMINALLY-ILL CANCER PATIENTS RESIDENT IN PARMA PROVINCE: RATES OF HOSPITALISATION, USE OF HOME CARE AND HOSPICE SERVICES AND PRESCRIPTION OF CHEMOTHERAPY NEAR TO DEATH

Author

Franciosi V, Sgargi P, Melegari E, Bozzani F, Gnappi D, Michiara M, Vasini G, Salvagni S, Bacchini GP, Ghisoni F, De Lisi V, ARDIZZONI, ANDREA, Franciosi V, Sgargi P, Melegari E, Bozzani F, Gnappi D, Michiara M, Vasini G, Salvagni S, Bacchini GP, Ghisoni F, De Lisi V, and Ardizzoni A

Subjects
PALLIATIVE CARE FOR TERMINALLY-ILL CANCER PATIENTS RESIDENT IN PARMA PROVINCE: RATES OF HOSPITALISATION, USE OF HOME CARE AND HOSPICE SERVICES AND PRESCRIPTION OF CHEMOTHERAPY NEAR TO DEATH
Published
2009

22. Robust Axonal Regeneration Occurs in the Injured CAST/Ei Mouse CNS

Author

Omura, T, Omura, K, Tedeschi, A, Riva, P, Painter, MW, Rojas, L, Martin, J, Lisi, V, Huebner, EA, Latremoliere, A, Yin, Y, Barrett, LB, Singh, B, Lee, S, Crisman, T, Gao, F, Li, S, Kapur, K, Geschwind, DH, Kosik, KS, Coppola, G, He, Z, Carmichael, ST, Benowitz, LI, Costigan, M, and Woolf, CJ

Subjects
nervous system
Abstract

© 2015 Elsevier Inc. Axon regeneration in the CNS requires reactivating injured neurons' intrinsic growth state and enabling growth in an inhibitory environment. Using an inbred mouse neuronal phenotypic screen, we find that CAST/Ei mouse adult dorsal root ganglion neurons extend axons more on CNS myelin than the other eight strains tested, especially when pre-injured. Injury-primed CAST/Ei neurons also regenerate markedly in the spinal cord and optic nerve more than those from C57BL/6 mice and show greater sprouting following ischemic stroke. Heritability estimates indicate that extended growth in CAST/Ei neurons on myelin is genetically determined, and two whole-genome expression screens yield the Activin transcript Inhba as most correlated with this ability. Inhibition of Activin signaling in CAST/Ei mice diminishes their CNS regenerative capacity, whereas its activation in C57BL/6 animals boosts regeneration. This screen demonstrates that mammalian CNS regeneration can occur and reveals a molecular pathway that contributes to this ability. Omura etal. screened for neuronal growth on myelin and find CAST/Ei inbred mice are uniquely able to regenerate axons in the injured CNS through Activin signaling. Enhancing Activin signaling confers a CNS-regenerative capacity in normally non-regenerative mouse strains.

Published
2014
Full Text
View/download PDF

24. Prevalence of H. pylori CagA+ve in suburban area with high incidence of gastric cancer

Author

FRANZ A, NERVI G, COMPARATO G, MOUSSA AM, DE LISI V, CARLONI C, LIATOPOULOU S, ARAGONA G, CAVALLARO LG, IORI V, MAINO M, MARCUCCI F, DI MARIO F., CAVESTRO , GIULIA MARTINA, Franz, A, Nervi, G, Comparato, G, Moussa, Am, DE LISI, V, Carloni, C, Liatopoulou, S, Aragona, G, Cavallaro, Lg, Cavestro, GIULIA MARTINA, Iori, V, Maino, M, Marcucci, F, and DI MARIO, F.

Published
2003

25. Prevalence of CagA status in an high risk area for gastric carcinoma

Author

FRANZ A, NERVI G, COMPARATO G, MOUSSA AM, DE LISI V, DI COLA G, CARLONI C, LIATOPOLOU S, CAVALLARO LG, IORI V, DI MARIO F., CAVESTRO , GIULIA MARTINA, Franz, A, Nervi, G, Comparato, G, Moussa, Am, DE LISI, V, DI COLA, G, Carloni, C, Liatopolou, S, Cavallaro, Lg, Cavestro, GIULIA MARTINA, Iori, V, and DI MARIO, F.

Published
2003

27. [Survival for all cancers is increasing, especially in men, but only thanks to PSA]

Author

Coviello, E, Rashid, I, Buzzoni, C, Fusco, M, Bisanti, L, Sechi, O, Candela, G, Crosignani, P, De Lisi, V, Donato, A, Mangoni, M, Falcini, F, Federico, Massimo, Gennaro, V, Giacomin, A, La Rosa, F, Madeddu, A, Contrino, Ml, Mangone, L, Mazzoleni, G, Pannozzo, F, Zanetti, R, Cocchioni, M, Piffer, S, Pisani, P, PONZ DE LEON, Maurizio, Ricci, P, Serraino, D, Sutera, A, Tessandori, R, Traina, A, Tumino, R, Usala, M, Vercelli, M, Vitarelli, S, Zambon, P, Crocetti, E, Ferretti, S, Gola, G, and Sciacca, S.

Subjects
Male, Survival Rate, PSA, Sex Factors, Italy, Neoplasms, prostate cancer survival, Humans, Prostatic Neoplasms, Female, Prostate-Specific Antigen, survival
Published
2013

28. Predictions of survival up to 10 years after diagnosis for european women with breast cancer in 2000-2002

Author

Allemani, Claudia, Minicozzi, Pamela, Berrino, Franco, Bastiaannet, Esther, Gavin, Anna, Galceran, Jaume, Ameijide, Alberto, Siesling, Sabine, Mangone, Lucia, Ardanaz, Eva, Hã©delin, Guy, Mateos, Antonio, Micheli, Andrea, Sant, Milena, Holub, J., Jurickova, L., Hakulinen, T., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Margutti, C., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Ferretti, S., Federico, M., Rashid, I., Cirilli, C., De Lisi, V., Bozzani, F., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Falcini, F., Foca, F., Giorgetti, S., Paci, E., Crocetti, E., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mä™å¼yk, R., Bielska-Lasota, M., Zwierko, M., Safaei Diba, C., Primič-Žakelj, M., Klint, Ã. …., Talbã¤ck, M., Usel, M., Ess, S. M., Lutz, J. M., Pury, P., Visser, O., Greenberg, D. C., Coleman, M. P., Woods, L., Forman, D., Cooper, N., Roche, M., Lawrence, G., Black, R. J., Brewster, D. H., and Steward, J. A.

Subjects
Adult, medicine.medical_specialty, Cancer Research, Adolescent, Population, breast cancer, cancer survival, Socio-culturale, Breast Neoplasms, Disease, Breast cancer, Age Distribution, medicine, 80 and over, Humans, Registries, Stage (cooking), education, Survival rate, Survival analysis, EUROCARE, long-term survival, stage, Aged, Aged, 80 and over, Europe, Female, Middle Aged, Prognosis, Survival Analysis, Survival Rate, Oncology, Gynecology, education.field_of_study, Relative survival, business.industry, Cancer, medicine.disease, business, Demography
Abstract

Few studies have addressed longer-term survival for breast cancer in European women. We have made predictions of 10-year survival for European women diagnosed with breast cancer in 2000-2002. Data for 114,312 adult women (15-99 years) diagnosed with a first primary malignant cancer of the breast during 2000-2002 were collected in the EUROCARE-4 study from 24 population-based cancer registries in 14 European countries. We estimated relative survival at 1, 5, and 10 years after diagnosis for women who were alive at some point during 2000-2002, using the period approach. We also estimated 10-year survival conditional on survival to 1 and 5 years after diagnosis. Ten-year survival exceeded 70% in most regions, but was only 54% in Eastern Europe, with the highest value in Northern Europe (about 75%). Ten-year survival conditional on survival for 1 year was 2-6% higher than 10-year survival in all European regions, and geographic differences were smaller. Ten-year survival for women who survived at least 5 years was 88% overall, with the lowest figure in Eastern Europe (79%) and the highest in the UK (91%). Women aged 50-69 years had higher overall survival than older and younger women (79%). Six cancer registries had adequate information on stage at diagnosis; in these jurisdictions, 10-year survival was 89% for local, 62% for regional and 10% for metastatic disease. Data on stage are not collected routinely or consistently, yet these data are essential for meaningful comparison of population-based survival, which provides vital information for improving breast cancer control. What's new? Policy-makers and health-care planners need accurate data on long-term survival to improve cancer control. This Europe-wide study of 10-year survival identified low survival in Eastern Europe for women with breast cancer in 2000-2002, and wide variation by age at diagnosis. Data on stage at diagnosis are crucial for meaningful comparison of population-based survival, and fundamental for improving breast cancer control, but our analyses confirmed that stage data are not collected routinely or consistently

Published
2013

29. Changes in the incidence of thyroid cancer between 1991 and 2005 in Italy: a geographical analysis

Author

Lise, M, Franceschi, S, Buzzoni, C, Zambon, P, Falcini, F, Crocetti, E, Serraino, D, Iachetta, F, Zanetti, R, Vercelli, Marina, Ferretti, S, LA ROSA, F, Donato, A, DE LISI, V, Mangone, L, Busco, S, Tagliabue, G, Budroni, M, Bisanti, L, Fusco, M, Limina, Rm, Tumino, R, Piffer, S, Madeddu, A, Bellù, F, Giacomin, A, Candela, G, Anulli, Ml, DAL MASO, L, and AIRTUM WORKING GROUP

Subjects
Adult, Male, geographical analysis, Joinpoint regression, cancer incidence, Endocrinology, Diabetes and Metabolism, Thyroid cancer, thyroid, Thyroid carcinoma, Endocrinology, Sex Factors, Medicine, Humans, Registries, Thyroid Neoplasms, Incidence, Italy, thyroid cancer, geographical patterns, time trends, Aged, Geography, Time trends, business.industry, Incidence (epidemiology), Carcinoma, Cancer, Environmental Exposure, Middle Aged, medicine.disease, Annual Percent Change, Carcinoma, Papillary, Thyroid Cancer, Papillary, Female, business, Demography
Abstract

The incidence of thyroid cancer (TC) has been increasing over the last 30 years in several countries, with some of the worldwide highest TC incidence rates (IRs) reported in Italy. The objectives of this study were to evaluate by histological subtypes the geographical heterogeneity of the incidence of TC in Italy and to analyze recent time trends for papillary thyroid carcinoma (PTC) in different cancer registries (CRs).The study included cases of TC (85 years of age) reported to 25 Italian CRs between 1991 and 2005. Age-standardized IRs were computed for all histological subtypes of TC according to CRs. Estimated annual percent change and joinpoint regression analysis were used for analysis of PTC.In women, IRs of PTC ranged between 3.5/100,000 in Latina and 8.5/100,000 in Sassari for the period 1991-1995 (a 2.4-fold difference) and between 7.3/100,000 in Alto Adige and 37.5/100,000 in Ferrara for 2001-2005 (a 5.1-fold difference). In men, IRs ranged between 0.7/100,000 in Latina and 3.4/100,000 in Sassari for the period 1991-1995 (a 4.9-fold difference) and between 2.0/100,000 (Alto Adige, Trento) and 10.6/100,000 in Ferrara for 2001-2005 (a 5.3-fold difference). In both sexes, IRs significantly higher than the pooled estimates emerged for the most recent period in the majority of CRs located within the Po River plain and in Latina, but they were lower in the Alpine belt. For women, CRs reported higher IRs than pool estimates showed, between 1991 to 2005, a significantly more marked annual percent change (+12%) than other CRs (+7%). For men the corresponding estimates were +11% and +8%.The distribution of PTC does not lend support to a role of environmental radiation exposure due to the Chernobyl fallout, iodine deficiency, or (volcanic) soils. Between 1991 and 2005, wide geographic variations in the incidence of PTC and heterogeneous upward trends emerged, suggesting that the heterogeneity was a relatively recent phenomenon; this appeared to be mainly explained by variations, at a local level, in medical surveillance.

Published
2012

30. RNA-Puzzles: A CASP-like evaluation of RNA three-dimensional structure prediction

Author

Patel, D. J., Tuszynska, I., Santalucia, J., Das, R., Ding, F., Sripakdeevong, P., Mikolajczak, K., Cruz, J. A., Dokholyan, N. V., Puton, T., Skorupski, M., Bujnicki, J. M., Rother, K., Soltysinski, T., Lisi, V., Leontis, N. B., Wildauer, M., Serganov, A., Cao, S., Waldsich, C., Lavender, C. A., Weeks, K. M., Sijenyi, F., Major, F., Blanchet, M.-F., Flores, S. C., Hermann, T., Chen, S.-J., Philips, A., Boniecki, M., Huang, L., and Rother, M.

Abstract

We report the results of a first, collective, blind experiment in RNA three-dimensional (3D) structure prediction, encompassing three prediction puzzles. The goals are to assess the leading edge of RNA structure prediction techniques; compare existing methods and tools; and evaluate their relative strengths, weaknesses, and limitations in terms of sequence length and structural complexity. The results should give potential users insight into the suitability of available methods for different applications and facilitate efforts in the RNA structure prediction community in ongoing efforts to improve prediction tools. We also report the creation of an automated evaluation pipeline to facilitate the analysis of future RNA structure prediction exercises.

Published
2012
Full Text
View/download PDF

31. Oesophageal cancer survival in Europe: A EUROCARE-4 study

Author

Gavin, A. T., Francisci, S., Foschi, R., Donnelly, D. W., Lemmens, V., Brenner, H., Anderson, L. A., Oberaigner, W., Hackl, M., Van Eycken, E., Henau, K., Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Casella, I., Margutti, C., Ciccolallo, L., Gatta, G., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Vitarelli, S., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., England, K., Micallef, R., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Go´ z´dz´, S., Siudowska, U., Me?z? yk, R., Bielska-Lasota, M., Sklodowska, M., Zwierko, M., Miranda, A., Diba, C. S., Plesko, I., Primic-Z?akelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, O., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Saâ´nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talbaâck, M., Khan, S., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Konzelmann, I., Dehler, S., Lutz, J. M., Pury, P., Siesling, S., Visser, O., Otter, R., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, L., Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Black, R. J., Brewster, D. H., Steward, J. A., Bouchardy Magnin, Christine, and Usel, Massimo

Subjects
Stage, Adult, Male, Cancer Research, Survival, Adolescent, Esophageal Neoplasms, Epidemiology, Socio-culturale, Subtype, Disease, Europe/epidemiology, Young Adult, Cancer, Europe, Oesophagus, Trends, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Registries, Survival Rate, Oncology, medicine, 80 and over, Young adult, Stage (cooking), cancer survival, Survival rate, ddc:613, Relative survival, business.industry, Oesophageal cancer, Cancer survival, medicine.disease, Esophageal Neoplasms/mortality/pathology, business, Demography, Cohort study
Abstract

Oesophageal cancer survival is poor with variation across Europe. No pan-European studies of survival differences by oesophageal cancer subtype exist. This study investigates rates and trends in oesophageal cancer survival across Europe. Data for primary malignant oesophageal cancer diagnosed in 1995-1999 and followed up to the end of 2003 was obtained from 66 cancer registries in 24 European countries. Relative survival was calculated using the Hakulinen approach. Staging data were available from 19 registries. Survival by region, gender, age, morphology and stage was investigated. Cohort analysis and the period approach were applied to investigate survival trends from 1988 to 2002 for 31 registries in 17 countries. In total 51,499 cases of oesophageal cancer diagnosed 1995-1999 were analysed. Overall, European 1- and 5-year survival rates were 33.4% (95% CI 32.9-33.9%) and 9.8% (95% CI 9.4-10.1%), respectively. Males, older patients and patients with late stage disease had poorer 1- and 5-year relative survival. Patients with squamous cell carcinoma had poorer 1-year relative survival. Regional variation in survival was observed with Central Europe above and Eastern Europe below the European pool. Survival for distant stage disease was similar across Europe while survival rates for localised disease were below the European pool in Eastern and Southern Europe. Improvement in European 1-year relative survival was reported (p=0.016). Oesophageal cancer survival was poor across Europe. Persistent regional variations in 1-year survival point to a need for a high resolution study of diagnostic and treatment practices of oesophageal cancer.

Published
2012

32. Survival of European patients with central nervous system tumors

Author

Sant, Milena, Minicozzi, Pamela, Lagorio, Susanna, Børge Johannesen, Tom, Marcos-Gragera, Rafael, Francisci, Silvia, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Guizard, A. V., Danzon, A., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Margutti, C., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., De Lisi, V., Bozzani, F., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Miranda, A., Safaei Diba, Chakameh, Primic-Źakelj, M., Izarzugaza, I., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Lutz, J. M., Pury, P., Visser, O., Otter, R., Siesling, S., van der Zwan, J. M., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., van der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., and Usel, Massimo

Subjects
Oncology, Ependymoma, Adult, Male, medicine.medical_specialty, Pathology, Cancer Research, Adolescent, Central Nervous System Neoplasms/mortality, Population, survival, NO, Benign tumor, Central Nervous System Neoplasms, Young Adult, Sex Factors, Internal medicine, morphology, medicine, 80 and over, Humans, Registries, Young adult, central nervous system tumors, Europe, Age Factors, Aged, Aged, 80 and over, Female, Middle Aged, Survival Rate, education, Survival rate, ddc:613, Medulloblastoma, education.field_of_study, Relative survival, business.industry, Cancer survival, Cancer, central nervous system tumors, survival, morphology, Europe, medicine.disease, business
Abstract

We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant tumors. Benign tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant tumors only). For glial tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma tumors from 96.5% (neurinoma) to 44.9% (primitive neuroectoderm tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers.

Published
2011

33. [Population ageing effect on number of cancer cases: Italian cancer registries data]

Author

Buzzoni, C, Bisanti, L, Budroni, M, Candela, G, Crosignani, P, De Lisi, V, Donato, A, Donato, F, Falcini, F, Federico, Massimo, Fusco, M, Gennaro, V, Giacomin, A, La Rosa, F, Madeddu, A, Contrino, Ml, Mangone, L, Mazzoleni, G, Pannozzo, F, Pascucci, C, Cocchioni, M, Piffer, S, Pisani, P, PONZ DE LEON, Maurizio, Ricci, P, Serraino, D, Sutera, A, Tessandori, R, Traina, A, Tumino, R, Usala, M, Vercelli, M, Vitarelli, S, Zambon, P, Zanetti, R, Crocetti, E, Paci, E, and Ferretti, S.

Subjects
Adult, Aged, 80 and over, Male, Adolescent, Incidence, Population Dynamics, Infant, Newborn, Infant, registries, Middle Aged, Young Adult, Age Distribution, Italy, age, Child, Preschool, Neoplasms, age, cancer, registries, Humans, cancer, Female, Disease Susceptibility, Registries, Child, Aged
Abstract

To describe causes of cancer incidence increase. We identified and quantified a population ageing factor, a factor due to incidence trend of cancer sites with early-diagnosis interventions and a remainder factor (concerning all other cancer sites).We calculated incidence rates for two calendar period (1993-95 and 2003-05).We used data from Cancer Registries with at least one incidence year available for each period (jointly for males and female). We compared crude and age-adjusted rates by the direct method for prostate cancer, breast cancer, colorectal cancer, melanoma of the skin cancer, thyroid cancer, group of other cancer sites and for all cancer sites (but non-melanoma skin cancer).Since 1993-95 to 2003-05 all cancer crude incidence rates have been increasing 17.9% (from 555.4 cases for 100,000 inhabitants/years to 654.8). If population age structure had remained the same, rates would have increased only 6.6% (from 555.4 to 592.0): almost 2/3 of observed increasing are due to population ageing. The remainder part of the increasing is due to incidence trend of cancer sites with early-diagnosis interventions (that anticipates the diagnosis).This study helps to quantify the incidence increase due to population ageing and the raise due to trend of cancer sites with early-diagnosis interventions.

Published
2011

34. Italian cancer figures: North and South are getting closer

Author

Buzzoni, C, Bisanti, L, Budroni, M, Candela, G, Crosignani, P, De Lisi, V, Donato, A, Donato, F, Falcini, F, Federico, Massimo, Fusco, M, Gennaro, V, Giacomin, A, La Rosa, F, Madeddu, A, Contrino, Ml, Mangone, L, Mazzoleni, G, Pannozzo, F, Pascucci, C, Cocchioni, M, Piffer, S, Pisani, P, PONZ DE LEON, Maurizio, Ricci, P, Serraino, D, Sutera, A, Tessandori, R, Traina, A, Tumino, R, Usala, M, Vercelli, M, Vitarelli, S, Zambon, P, Zanetti, R, Crocetti, E, and Ferretti, S.

Subjects
Male, Italy, Socioeconomic Factors, Neoplasms, Humans, Female, Cancer
Published
2011

37. Cancer incidence in people with AIDS in Italy

Author

Polesel, J, Franceschi, S, Suligoi, B, Crocetti, E, Falcini, F, Guzzinati, S, Vercelli, M, Zanetti, R, Tagliabue, G, Russo, A, Luminari, S, Stracci, F, De Lisi, V, Ferretti, Stefano, Mangone, L, Budroni, M, Limina, Rm, Piffer, S, Serraino, D, Bellù, F, Giacomin, A, Donato, A, Madeddu, A, Vitarelli, S, Fusco, M, Tessandori, R, Tumino, R, Piselli, P, Dal Maso, L, Cancer, AIDS Registries Linkage Study Cancer, AIDS Registries Linkage Study, Lise, M, Zucchetto, A, De Paoli, A, Intrieri, T, Vattiato, R, Zambon, P, Puppo, A, Patriarca, S, Tittarelli, A, Autelitano, M, Cirilli, C, La Rosa, F, Sgargi, P, Di Felice, E, Cesaraccio, R, Donato, F, Franchini, S, Zanier, L, Vittadello, F, Vercellino, Pc, Senatore, G, Contrino, Ml, Antonini, S, Palombino, R, Maspero, S, La Rosa MG, Camoni, L, and Regine, V.

Subjects
AIDS, HAART, cancer incidence, lung cancer, liver cancer
Published
2010

38. Survival trends in European cancer patients diagnosed from 1988 to 1999

Author

Verdecchia, Arduino, Guzzinati, Stefano, Francisci, Silvia, De Angelis, Roberta, Bray, Freddie, Allemani, Claudia, Tavilla, Andrea, Santaquilani, Mariano, Sant, Milena, Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, Survival, MESH : Mortality, MESH : Age Distribution, MESH : Aged, Colonoscopy, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Prostate, Residence Characteristics, Neoplasms, 80 and over, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH: Residence Characteristics, Young adult, cancer survival, MESH : Sex Distribution, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, Relative survival, Europe, Population registries, Time trends, Adolescent, Adult, Age Distribution, Aged, Female, Humans, Middle Aged, Mortality, Sex Distribution, Survival Analysis, Young Adult, Oncology, MESH: Sex Distribution, MESH : Adult, 3. Good health, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, medicine.medical_specialty, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, Rectum, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, MESH : Adolescent, medicine, MESH : Middle Aged, MESH : Aged, 80 and over, Cervix, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Surgery, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

International audience; We analysed data from 49 cancer registries in 18 European countries over the period 1988-1999 to delineate time trends in cancer survival. Survival increased in Europe over the study period for all cancer sites that were considered. There were major survival increases in 5 year age-adjusted relative survival for prostate (from 58% to 79%), colon and rectum (from 48% to 54% men and women), and breast (from 74% to 83%). Improvements were also significant for stomach (from 22% to 24%), male larynx (from 62% to 64%), skin melanoma (from 78% to 83%), Hodgkin disease (from 77% to 83%), non-Hodgkin lymphoma (from 49% to 56%), leukaemias (from 37% to 42%), and for all cancers combined (from 34% to 39% in men, and from 52% to 59% in women). Survival did not change significantly for female larynx, lung, cervix or ovary. The largest increases in survival typically occurred in countries with the lowest survival, and contributed to the overall reduction of survival disparities across Europe over the study period. Differences in the extent of PSA testing and mammographic screening, and increasing use of colonoscopy and faecal blood testing together with improving cancer care are probably the major underlying reasons for the improvements in survival for cancers of prostate, breast, colon and rectum. The marked survival improvements in countries with poor survival may indicate that these countries have made efforts to adopt the new diagnostic procedures and the standardised therapeutic protocols in use in more affluent countries.

Published
2009
Full Text
View/download PDF

39. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis

Author

De Angelis, Roberta, Francisci, Silvia, Baili, Paolo, Marchesi, Francesca, Roazzi, Paolo, Belot, Aurã©lien, Crocetti, Emanuele, Pury, Pierre, Knijn, Arnold, Coleman, Michel, Capocaccia, Riccardo, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Service de Biostatistique, Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Cancer Research, MESH: Quality Control, computer.software_genre, MESH: Epidemiologic Methods, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Medicine, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, education.field_of_study, Database, Relative survival, Incidence (epidemiology), Europe, Population registries, Survival analysis, Vital statistics, Databases as Topic, Epidemiologic Methods, Humans, Quality Control, Oncology, MESH : Quality Control, 3. Good health, 030220 oncology & carcinogenesis, Population, MESH : Europe, MEDLINE, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Epidemiologic Methods, 03 medical and health sciences, education, MESH: Humans, business.industry, MESH : Humans, Cancer, medicine.disease, MESH : Neoplasms, Data quality, MESH: Europe, MESH : Databases as Topic, business, computer, MESH: Databases as Topic, International Classification of Diseases for Oncology
Abstract

International audience; This paper describes the collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database. Methods for estimating relative survival are also described. Incidence and vital status data on newly diagnosed European cancer cases were received from 93 cancer registries in 23 countries, covering 151,400,000 people (35% of the participating country population). The third revision of the International Classification of Diseases for Oncology was used to specify tumour topography and morphology. Records were extensively checked for consistency and compatibility using multiple routines; flagged records were sent back for correction. An algorithm assigned standardised sequence numbers to multiple cancers. Only first malignant cancers were used to estimate relative survival from registry, year, sex and age-specific life tables. Age-adjusted and Europe-wide survival were also estimated. The database contains 13,814,573 cases diagnosed in 1978-2002; 92% malignant. A negligible proportion of records was excluded for major errors. Of 5,753,934 malignant adult cases diagnosed in 1995-2002, 5.3% were second or later cancers, 2.7% were known from death certificates only and 0.4% were discovered at autopsy. The remaining 5,278,670 cases entered the survival analyses, 90% of these had microscopic confirmation and 1.3% were censored alive after less than five years' follow-up. These indicators suggest satisfactory data quality that has improved since EUROCARE-3.

Published
2009
Full Text
View/download PDF

40. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary

Author

Sant, Milena, Allemani, Claudia, Santaquilani, Mariano, Knijn, Arnold, Marchesi, Francesca, Capocaccia, Riccardo, Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Epidemiology, Medicine, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH : Sex Distribution, MESH: Aged, MESH: Middle Aged, Relative survival, MESH: Sex Distribution, Population-based cancer registries, Middle Aged, MESH : Adult, Cancer survival, EUROCARE, Adolescent, Adult, Age Distribution, Aged, Europe, Female, Humans, Sex Distribution, Survival Analysis, Oncology, 3. Good health, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Skin melanoma, Stage at diagnosis, medicine.medical_specialty, MESH : Male, MESH : Europe, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Age and sex, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, Advanced stage, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, Demography
Abstract

International audience; EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in 23 European countries, diagnosed in 1995-1999 and followed to December 2003. For each cancer site, the mean European area-weighted observed and relative survival at 1-, 3-, and 5-years by age and sex are presented. Country-specific 1- and 5-year relative survival is also shown, together with 5-year relative survival conditional to surviving 1-year. Within-country variation in survival is analysed for selected cancers. Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis (breast, colorectum, stomach, skin melanoma), was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia. France, Switzerland and Italy generally had high survival, slightly below that in the northern countries. There were between-region differences in the survival for haematologic malignancies, possibly due to differences in the availability of effective treatments. Survival of elderly patients was low probably due to advanced stage at diagnosis, comorbidities, difficult access or lack of availability of appropriate care. For all cancers, 5-year survival conditional to surviving 1-year was higher and varied less with region, than the overall relative survival.

Published
2009
Full Text
View/download PDF

41. Pattern of cancer risk in persons with AIDS in Italy in the HAART era

Author

Dal Maso, L, Polesel, J, Serraino, D, Lise, M, Piselli, P, Falcini, F, Russo, A, Intrieri, T, Vercelli, M, Zambon, P, Tagliabue, G, Zanetti, R, Federico, M, Limina, Rm, Mangone, L, De Lisi, V, Stracci, Fabrizio, Ferretti, S, Piffer, S, Budroni, M, Donato, A, Giacomin, A, Bellù, F, Fusco, M, Madeddu, A, Vitarelli, S, Tessandori, R, Tumino, R, Suligoi, B, Franceschi, S, Cancer, AIDS Registries Linkage Study, and LA ROSA, Francesco

Published
2009

42. Pattern of Cancer risk in person with AIDS in Italy in the HAART era

Author

Dal Maso, L., Polesel, J., Serraino, D., Lise, M., Pierluca Piselli, Falcini, F., Russo, A., Intrieri, T., Vercelli, M., Zambon, P., Tagliabue, G., Zanetti, R., Federico, M., LIMINA RM, Mangone, L., Lisi, V., Stracci, F., Ferretti, S., Piffer, S., Budroni, M., Donato, A., Giacomin, A., Bellù, F., Fusco, M., Madeddu, A., Vitarelli, S., Tessandori, R., Tumino, R., Suligoi, B., and Franceschi, S.

Subjects
AIDS, HAART, hepatitis viruses, epidemiology, human papillomavirus
Published
2009

43. The cure of cancer: a european perspective

Author

Francisci, Silvia, Capocaccia, Riccardo, Grande, Enrico, Santaquilani, Mariano, Simonetti, Arianna, Allemani, Claudia, Gatta, Gemma, Sant, Milena, Zigon, Giulia, Bray, Freddie, Janssen-Heijnen, Maryska, Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, Colorectal cancer, MESH : Age Distribution, MESH : Aged, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Prostate cancer, 0302 clinical medicine, Breast cancer, MESH: Aged, 80 and over, Colon and rectum cancer, Cure, Lung cancer, Relative survival, Statistical models, Stomach cancer, Oncology, Neoplasms, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, Aged, 80 and over, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Middle Aged, MESH : Adult, Prognosis, 3. Good health, Europe, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Female, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Young Adult, Age Distribution, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH: Age Distribution, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Survival Analysis, MESH : Neoplasms, MESH: Male, Cancer registry, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

International audience; Cancer survival analyses based on cancer registry data do not provide direct information on the main aim of cancer treatment, the cure of the patient. In fact, classic survival indicators do not distinguish between patients who are cured, and patients who will die of their disease and in whom prolongation of survival is the main objective of treatment. In this study, we applied parametric cure models to the cancer incidence and follow-up data provided by 49 EUROCARE-4 (European Cancer Registry-based study, fourth edition) cancer registries, with the aims of providing additional insights into the survival of European cancer patients diagnosed from 1988 to 1999, and of investigating between-population differences. Between-country estimates the proportion of cured patients varied from about 4-13% for lung cancer, from 9% to 30% for stomach cancer, from 25% to 49% for colon and rectum cancer, and from 55% to 73% for breast cancer. For all cancers combined, estimates varied between 21% and 47% in men, and 38% and 59% in women and were influenced by the distribution of cases by cancer site. Countries with high proportions of cured and long fatal case survival times for all cancers combined were characterised by generally favourable case mix. For the European pool of cases both the proportion of cured and the survival time of fatal cases were associated with age, and increased from the early to the latest diagnosis period. The increases over time in the proportions of Europeans estimated cured of lung, stomach and colon and rectum cancers are noteworthy and suggest genuine progress in cancer control. The proportion of cured of all cancers combined is a useful general indicator of cancer control as it reflects progress in diagnosis and treatment, as well as success in the prevention of rapidly fatal cancers.

Published
2009
Full Text
View/download PDF

44. Long-term survival expectations of cancer patients in Europe in 2000-2002

Author

Brenner, Hermann, Francisci, Silvia, De Angelis, Roberta, Marcos-Gragera, Rafael, Verdecchia, Arduino, Gatta, Gemma, Allemani, Claudia, Ciccolallo, Laura, Coleman, Michel, Sant, Milena, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Gerontology, Male, Cancer Research, MESH: Registries, Survival, MESH : Life Expectancy, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Neoplasms, 80 and over, Medicine, Cancer registries, MESH: Neoplasms, MESH : Female, 030212 general & internal medicine, Registries, Young adult, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, Relative survival, MESH : Adult, Middle Aged, MESH : Survival Rate, Prognosis, 3. Good health, Europe, Survival Rate, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Cohort, Period Analysis, Female, cancer survival - long term, MESH: Life Expectancy, Adult, MESH: Survival Rate, Period analysis, Adolescent, Age Distribution, Aged, Humans, Life Expectancy, Survival Analysis, Young Adult, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH : Aged, 80 and over, Survival rate, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Life expectancy, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, MESH : Registries, Demography
Abstract

International audience; Period analysis has been shown to provide more up-to-date estimates of long-term cancer survival rates than traditional cohort-based analysis. Here, we provide detailed period estimates of 5- and 10-year relative survival by cancer site, country, sex and age for calendar years 2000-2002. In addition, pan-European estimates of 1-, 5- and 10-year relative survival are provided. Overall, survival estimates were mostly higher than previously available cohort estimates. For most cancer sites, survival in countries from Northern Europe, Central Europe and Southern Europe was substantially higher than in the United Kingdom and Ireland and in countries from Eastern Europe. Furthermore, relative survival was also better in female than in male patients and decreased with age for most cancer sites.

Published
2009
Full Text
View/download PDF

45. Incidenza dei tumori ematologici nelle aree italiane

Author

Allemani, C., Minicozzi, P., DE ANGELIS, R., Tereanu, C., Berrino, F., Bellù, F., Cesaraccio, R., DE LISI, V., Donato, A., Falcini, F., Ferretti, S., Fiore, A. R., Fusco, M., Giacomin, A., Luminari, S., Mangone, L., Paci, E., Piffer, S., Scheibel, M., Serraino, D., Tumino, R., Vercelli, Marina, and Sant, R. ZANETTI E. M.

Published
2009

46. Comparative cancer survival information in Europe

Author

Berrino, Franco, Verdecchia, Arduino, Lutz, Jean Michel, Lombardo, Claudio, Micheli, Andrea, Capocaccia, Riccardo, Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Registre Genevois des Tumeurs, CHU Genève, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Male, Pathology, medicine.medical_specialty, Cancer Research, MESH : Male, MESH : Europe, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Publications, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Epidemiology of cancer, Medicine, Humans, MESH: Neoplasms, MESH : Female, 030212 general & internal medicine, Health planning, cancer survival, ComputingMilieux_MISCELLANEOUS, MESH: Humans, business.industry, Health Policy, MESH : Humans, Publications, Cancer survival, MESH : Publications, Descriptive epidemiology, MESH : Neoplasms, Survival Analysis, MESH: Male, 3. Good health, Europe, Female, Oncology, Chronic disease, MESH: Survival Analysis, 030220 oncology & carcinogenesis, MESH: Health Policy, MESH: Europe, MESH : Health Policy, MESH : Survival Analysis, business, MESH: Female, Humanities
Abstract

Franco Berrino*, Arduino Verdecchia, Jean Michel Lutz, Claudio Lombardo, Andrea Micheli, Riccardo Capocaccia, the EUROCARE Working Group Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, 20133 Milan, Italy National Centre for Epidemiology, Surveillance and Health Promotion, Department of Cancer Epidemiology, Istituto Superiore di Sanita, Viale Regina Elena 299, Rome, Italy Department of Chronic Disease Epidemiology, National Institute for Cancer Epidemiology and Registration (NICER), University of Zurich, Sumatrastrasse 30, Zurich, Switzerland Focal Point International Affairs Executive, Alleanza Contro il Cancro, IST Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10, Genova, Italy Descriptive Epidemiology and Health Planning Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy

Published
2009
Full Text
View/download PDF

47. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States

Author

Sant, Milena, Allemani, Claudia, De Angelis, Roberta, Carbone, Antonino, De SanJose, Silvia, Gianni, Alessandro M., Giraldo, Pilar, Marchesi, Francesca, Marcos-Gragera, Rafael, Martos-Jimenez, Carmen, Maynadie, Marc, Raphael, Martine, Berrino, Franco, Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., MacE-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estãve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Ferretti, S., Contil, E., Ramazzotti, V., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Capocaccia, R., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska-Lasota, M., Wronkowski, Z., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does-Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Mã¸ller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Steward, J. A., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Miguel Servet, Registre des hémopathies malignes de Côte d'Or, Laboratoire d'Hématologie, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospital Universitario Miguel Servet, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Oncology, Cancer Research, Survival, Lymphoma, MESH: Registries, MESH : Age Distribution, MESH : Aged, MESH : Child, Preschool, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Lymphoma, Non-Hodgkin, MESH : Child, MESH: Child, hemic and lymphatic diseases, 80 and over, Medicine, Registries, Child, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH : Prognosis, Relative survival, Lymphoma, Non-Hodgkin, EUROCARE, Non-Hodgkin's lymphoma, Population cancer registries, US SEER, Adolescent, Adult, Age Distribution, Aged, Child, Preschool, Europe, Feasibility Studies, Humans, Infant, Middle Aged, Prognosis, United States, Absolute risk reduction, MESH : Infant, MESH : Adult, MESH: Infant, 3. Good health, 030220 oncology & carcinogenesis, morphology - survival - non Hodgkin lymphoma - Europe - US, epidemiology, medicine.medical_specialty, MESH : United States, MESH : Feasibility Studies, MESH : Europe, Socio-culturale, Non-Hodgkin, [SDV.CAN]Life Sciences [q-bio]/Cancer, survival, MESH: Prognosis, cancer, 03 medical and health sciences, Internal medicine, MESH : Adolescent, MESH: United States, MESH : Lymphoma, Non-Hodgkin, MESH : Middle Aged, Preschool, MESH : Aged, 80 and over, MESH: Age Distribution, MESH: Adolescent, MESH: Humans, business.industry, MESH: Child, Preschool, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Confidence interval, Cancer registry, Hodgkin lymphoma, MESH: Europe, business, MESH: Feasibility Studies, MESH : Registries, 030215 immunology
Abstract

International audience; We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3 cancer registries, and 22,713 cases from 9 US SEER registries. Overall 5-year relative survival was 56.1% in EUROCARE west, 47.1% in EUROCARE east and 56.3% in SEER. Relative excess risk (RER) of death was 1.05 (95% confidence interval (CI) 1.01-1.10) in EUROCARE west, 1.52 (95% CI 1.44-1.60) in EUROCARE east (SEER reference). Excess risk of death was significantly above reference (diffuse B lymphoma) for Burkitt's and NOS lymphoma; not different for lymphoblastic and other T-cell; significantly below reference (in the order of decreasing relative excess risk) for NHL NOS, mantle cell/centrocytic, lymphoplasmacytic, follicular, small lymphocytic/chronic lymphocytic leukaemia, other specified NHL and cutaneous morphologies. Interpretation of marked variation in survival with morphology is complicated by classification inconsistencies. The completeness and standardisation of cancer registry morphology data needs to be improved.

Published
2008
Full Text
View/download PDF

50. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study

Author

Bielska-Lasota, M., Inghelmann, R., van de Poll-Franse, L., Capocaccia, R., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., Mace-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Esteve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Wronkowski, Z., Zwierko, M., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Primic-Zakelj, M., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Bouchardy, C., Coebergh, J. W. W., van der Does-van den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Moller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
MESH: Registries, MESH : Mortality, MESH : Aged, Uterine Cervical Neoplasms, Disease, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Female, Registries, MESH: Aged, Cervical cancer, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, MESH : Prognosis, Relative survival, Absolute risk reduction, Obstetrics and Gynecology, Middle Aged, MESH : Adult, Prognosis, MESH : Survival Rate, 3. Good health, MESH: Uterine Cervical Neoplasms, Europe, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Adult, medicine.medical_specialty, MESH: Survival Rate, Adolescent, Population, MESH : Uterine Cervical Neoplasms, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, Trends - cervical cancer - survival, 03 medical and health sciences, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Mortality, education, MESH : Aged, 80 and over, Survival rate, 030304 developmental biology, Aged, MESH: Adolescent, Gynecology, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, Population-based study, Survival, Trends, medicine.disease, MESH: Europe, business, MESH: Female, MESH : Registries, Demography
Abstract

International audience; OBJECTIVE: To evaluate trends in survival from cervical cancer in Europe and in European countries participating in the EUROCARE study as a function of age, morphology and stage at diagnosis. METHODS: Relative survival and relative excess risk of death within 5 years of diagnosis, as a function of age, morphology and stage, among 73,022 women aged 15-99 years diagnosed during 1983-1994 and followed up to 1999 in each of 18 European countries participating in the EUROCARE study, using data from 34 population-based cancer registries. RESULTS: Overall five-year relative survival was 62%, rising by 2% during the period 1983-1994. The highest survival occurred in Northern and Western Europe and the lowest in Central Europe. Survival falls with age at diagnosis, but mainly for localised disease. Survival is higher for adenocarcinoma in younger women, but higher for squamous cell carcinoma in older women. The proportions of younger women, localised cancer and adenocarcinoma all increased. The main improvements in survival were for women under 65, and for metastatic disease. CONCLUSIONS: Survival in Europe has improved slowly but steadily, but the trend is not geographically uniform. Central European countries and the UK saw little or no improvement, and survival in those countries remains the lowest among participating countries in Europe. Further reduction of cervical cancer mortality in Europe may be expected from expansion of screening, and improvement in the treatment of older women, and of metastatic disease.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results